Related Experiment Videos
Evidence from biomarkers and surrogate endpoints
1Center for Neurosciences, North Shore-Long Island Jewish Research Institute, Manhasset, New York 11030, USA. asfeigin@aol.com
Summary
Biomarkers (BMs) are crucial in neurology for disease diagnosis and therapy assessment. Surrogate endpoints (SEs), a type of BM, offer advantages but require careful validation for evaluating new neurological treatments.
Area of Science:
- Neurology
- Biomedical Science
- Clinical Research
Background:
- Biomarkers (BMs) are increasingly vital in neurological practice for diagnosis and disease management.
- Objective biological measures aid in assessing both clinical practice and experimental therapeutics.
Purpose of the Study:
- To explore the applications of biomarkers in evaluating neurological disease therapies.
- To discuss the strengths and weaknesses of biomarkers using neurological disease examples.
- To review the advantages and disadvantages of surrogate endpoints (SEs) in therapy evaluation.
Main Methods:
- Review of current literature on biomarkers and surrogate endpoints in neurology.
- Analysis of biomarker and SE utility in assessing therapeutic interventions.
- Discussion of evidence requirements for SE development and validation.
Main Results:
- Biomarkers provide objective measures for neurological disease assessment.
- Surrogate endpoints (SEs) can serve as proxies for clinical outcomes in therapy trials.
- Understanding pathophysiology drives the development of novel biomarkers.
Conclusions:
- Biomarkers and SEs are essential tools in modern neurological research and clinical practice.
- Careful consideration of evidence is necessary for the development and application of SEs.
- Biomarkers enhance the evaluation of new therapies for neurological disorders.